PROGRAMMES

Discover our current research programme, which highlights our commitment to groundbreaking studies and treatments, based on our expertise in iron metabolism.

Growing demand for intravenous iron therapies across existing, new and emerging treatment areas aligns with Pharmacosmos’ long-term commitment to treating iron deficiency. It remains the driving factor behind our research and development, the ongoing direction of our company, and our promise to patients around the world, now and tomorrow. Committed to advancing healthcare through clinical trials, we invite you to explore our ongoing trials that highlight our dedication to research and developing transformative therapies.

Clinical Trials

Discover our clinical programme.

Petadeferitrin

Pharmacosmos is developing petadeferitrin, a novel iron chelator, as a new treatment for patients with transfusional iron overload.